The Vanguard Group 13D and 13G filings for Kymera Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-30 11:12 am Purchase | 2025-03-31 | 13G | Kymera Therapeutics, Inc. KYMR | The Vanguard Group | 5,231,392 8.050% | 1,233,828 (+30.86%) | Filing |
| 2024-02-13 5:08 pm Purchase | 2023-12-29 | 13G | Kymera Therapeutics, Inc. KYMR | The Vanguard Group | 3,997,564 6.730% | 337,257 (+9.21%) | Filing |
| 2023-02-09 11:25 am Purchase | 2022-12-30 | 13G | Kymera Therapeutics, Inc. KYMR | The Vanguard Group | 3,660,307 6.670% | 703,133 (+23.78%) | Filing |
| 2022-02-10 08:22 am Purchase | 2021-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | The Vanguard Group | 2,957,174 5.750% | 2,957,174 (New Position) | Filing |